2 days ago · NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated...

In addition, Metsera has granted the underwriters a 30-day option to purchase up to an additional 2,291,666 shares of common stock at the initial public offering price less underwriting discounts and commissions. BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor are acting as joint bookrunners for the ...

2 days ago · Metsera, Inc., a clinical-stage biotechnology company specializing in obesity treatments through injectable and oral hormone analog peptides, announced the pricing of its initial public offering ...

2 days ago · Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech ...

3 days ago · Metsera and Maze Therapeutics priced initial public offerings on Jan. 30, 2025, listing their shares on the Nasdaq stock exchange. ... in a pair of new stock offerings priced Thursday. Metsera, an obesity drug developer, sold nearly 15.3 million shares at $18 apiece in an offering that ranks as one of the industry’s largest since 2022, ...

2 days ago · Metsera (Nasdaq: MTSR), a clinical-stage biotech company focused on developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides for obesity treatment, has announced the pricing of its initial public offering.The company is offering 15,277,778 shares of common stock at $18.00 per share, expecting to raise gross proceeds of approximately $275.0 million ...

2 days ago · A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care first-time share sales since October. Metsera Inc. raised $275 million in its ...

Nov 13, 2024 · Metsera Announces Pricing of Initial Public Offering Jan 07, 2025 Metsera Announces Positive Topline Phase 2a Clinical Data for its Ultra-Long Acting GLP-1 Receptor Agonist, MET-097i

1 day ago · After initially offering its common stock to the public at $18.00 per share, the company's shares opened for trading at a higher price of $25.50. The initial public offering (IPO) consisted of ...

1 day ago · 2d illustrations and photos. Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering.Metsera ...